Adaptimmune Therapeutics plc

NasdaqGS:ADAP Rapporto sulle azioni

Cap. di mercato: US$162.8m

Adaptimmune Therapeutics Crescita futura

Future criteri di controllo 0/6

Si prevede che gli utili di Adaptimmune Therapeutics diminuiranno del 12.3% all'anno, mentre si prevede che il fatturato annuo crescerà del 3.3% all'anno. Si prevede che l'EPS crescerà del 2.4% all'anno.

Informazioni chiave

-12.3%

Tasso di crescita degli utili

2.4%

Tasso di crescita dell'EPS

Biotechs crescita degli utili28.4%
Tasso di crescita dei ricavi3.3%
Rendimento futuro del capitale proprion/a
Copertura analitica

Good

Ultimo aggiornamento14 Nov 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Investors Give Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares A 32% Hiding

Nov 15
Investors Give Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares A 32% Hiding

The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%

Sep 26
The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%

Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions

Sep 12

Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024

Jul 03

Adaptimmune: Huge Opportunity Amid Their Setback With Genentech

Apr 26

Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet

Apr 16
Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry

Feb 22
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry

Adaptimmune: Drug Approval Now Imminent?

Feb 02

Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Dec 27
Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts

Nov 09
News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts

New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Mar 08
New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans

Feb 20
Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans

New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Nov 09
New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Adaptimmune Therapeutics: Depressed Despite Upcoming BLA

Sep 20

We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow

Sep 15
We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow

Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022

Aug 10
Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022

Gene editing companies benefitting from Roche deal with CAR-T player Poseida Therapeutics

Aug 03

Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022

Jun 29

Finally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLA

Jun 19

Adaptimmune Therapeutics: A Little More Patience May Be Profitable

Mar 06

Circling Back On Adaptimmune Therapeutics

Dec 15

We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate

Dec 02
We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate

Adaptimmune Therapeutics: Diverse Pipeline With Approval Looming

Sep 29

We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate

Aug 14
We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:ADAP - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/202678-146-58-1456
12/31/202542-155-60-2059
12/31/2024185-40-61-596
9/30/2024175-45-56-54N/A
6/30/2024141-72-47-44N/A
3/31/202418-163-138-136N/A
12/31/202360-114-146-141N/A
9/30/202371-95-132-124N/A
6/30/202371-91-145-127N/A
3/31/202371-114-150-125N/A
12/31/202227-165-172-142N/A
9/30/202218-175-40-10N/A
6/30/202212-176-29-7N/A
3/31/20229-171-123N/A
12/31/20216-158211N/A
9/30/20216-156-158-152N/A
6/30/20216-149-129-124N/A
3/31/20214-140-121-117N/A
12/31/20204-130-56-54N/A
9/30/20203-123-39-37N/A
6/30/20202-127-52-50N/A
3/31/20202-138-62-59N/A
12/31/20191-137-116-113N/A
9/30/20192-144-134-132N/A
6/30/201942-99-96-92N/A
3/31/201951-102-97-93N/A
12/31/201860-96-109-104N/A
9/30/201862-87-100-94N/A
6/30/201849-93N/A-91N/A
3/31/201843-69N/A-73N/A
12/31/201738-70N/A-54N/A
9/30/201742-58N/A-31N/A
6/30/201717-76N/A-59N/A
3/31/201714-78N/A-58N/A
12/31/201614-72N/A-48N/A
9/30/201610-73N/A-68N/A
6/30/201612-61N/A-53N/A
3/31/201615-55N/A-45N/A
12/31/201514-48N/A-32N/A
9/30/201513-19N/A-20N/A
6/30/201510-37N/A-30N/A
3/31/20157-16N/A-4N/A
12/31/20144-12N/A24N/A
9/30/20142-13N/A25N/A
6/30/20141-12N/A37N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che ADAP rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che ADAP rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che ADAP rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di ADAP ( 3.3% all'anno) crescerà più lentamente rispetto al mercato US ( 9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di ADAP ( 3.3% all'anno) crescerà più lentamente di 20% all'anno.


Previsioni di crescita dell'utile per azione


Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di ADAP è previsto essere elevato tra 3 anni


Scoprire le aziende in crescita